Works matching DE "APATINIB"

Results: 267

卡瑞利珠单抗联合阿帕替尼治疗Ⅱ—ⅢA 期驱动基因阴性非小细胞肺癌的疗效及安全性研究.

Published in:

Evaluation & Analysis of Drug-Use in Hospitals of China / Zhongguo Yiyuan Yongyao Pingjia yu Fenxi, 2025, v. 25, n. 5, p. 573, doi. 10.14009/j.issn.1672-2124.2025.05.013

By:

严正平;
陈诚;
梁小红;
金晶#

Publication type:

Article

Rechallenge of anti-PD-1 antibody combined with chemotherapy shows promising efficacy in the treatment of advanced metastatic hepatocellular carcinoma: A case report.

Published in:

2025

By:

Tan, Xiang;
Kang, Le;
Chen, Hao;
Liu, Xingyan;
Du, Chi

Publication type:

Case Study

Efficacy and safety of tyrosine kinase inhibitors in treating refractory thyroid cancer: A network meta-analysis.

Published in:

Journal of Chinese Pharmaceutical Sciences, 2025, v. 34, n. 5, p. 470, doi. 10.5246/jcps.2025.05.036

By:

Yixiao Zhu;
Lirong Zhang;
Wenhua Wu;
Huiting Lin;
Xiaoxia Wei

Publication type:

Article

Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma.

Published in:

Cancer Management & Research, 2025, v. 17, p. 905, doi. 10.2147/CMAR.S520937

By:

Zhang, Jiaran;
Tian, Huichun;
Mao, Lili;
Li, Caili;
Wei, Xiaoting;
Gu, Junjie;
Wang, Xuan;
Zhou, Li;
Lian, Bin;
Tang, Bixia;
Yan, Xieqiao;
Li, Siming;
Cui, Chuanliang;
Chi, Zhihong;
Sheng, Xinan;
Guo, Jun;
Si, Lu

Publication type:

Article

Apatinib modulates sorafenib-resistant hepatocellular carcinoma through inhibiting the EGFR/JNK/ERK signaling pathway.

Published in:

Oncology Research, 2025, v. 33, n. 6, p. 1459, doi. 10.32604/or.2025.060407

By:

FAN, DEXUE;
SU, WEI;
BI, ZHAOWEN;
WANG, XINXING;
XU, XIANWEN;
MA, MINGZE;
ZHU, LICHAO;
ZHANG, ZHENHAI;
GAO, JUNLIN

Publication type:

Article

Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.

Published in:

BMC Medicine, 2025, v. 23, n. 1, p. 1, doi. 10.1186/s12916-025-04159-y

By:

Kan, Xue-Feng;
Liang, Bin;
Zhang, Xiao-Lin;
Yu, Lei;
Luo, Yao-Chang;
Zhou, Shi;
Liu, Rui-Bao;
Xu, Guo-Hui;
Li, Hai-Liang;
Liao, Zheng-Yin;
Xiang, Hua;
Lu, Wei;
Xu, Lin-Feng;
Ma, Yi-Long;
Xia, Xiang-Wen;
Qian, Kun;
Dong, Xiang-Jun;
Xiong, Fu;
Song, Song-Lin;
Zhao, Chang

Publication type:

Article

Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.

Published in:

BMC Medicine, 2025, v. 23, n. 1, p. 1, doi. 10.1186/s12916-025-04159-y

By:

Kan, Xue-Feng;
Liang, Bin;
Zhang, Xiao-Lin;
Yu, Lei;
Luo, Yao-Chang;
Zhou, Shi;
Liu, Rui-Bao;
Xu, Guo-Hui;
Li, Hai-Liang;
Liao, Zheng-Yin;
Xiang, Hua;
Lu, Wei;
Xu, Lin-Feng;
Ma, Yi-Long;
Xia, Xiang-Wen;
Qian, Kun;
Dong, Xiang-Jun;
Xiong, Fu;
Song, Song-Lin;
Zhao, Chang

Publication type:

Article

Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives.

Published in:

Discover Oncology, 2024, v. 15, n. 1, p. 1, doi. 10.1007/s12672-024-01110-0

By:

Liu, Jianzhong;
Xia, Shuai;
Zhang, Baoyi;
Mohammed, Dina Mostafa;
Yang, Xiangliang;
Zhu, Yanhong;
Jiang, Xinnong

Publication type:

Article

Effect and Safety of Apatinib as Neoadjuvant Therapy in Locally Advanced Differentiated Thyroid Cancer: A Phase 2 Trial.

Published in:

Journal of the Endocrine Society, 2024, v. 8, n. 9, p. 1, doi. 10.1210/jendso/bvae132

By:

Qian, Kai;
Wang, Yunjun;
An, Ning;
Liu, Chunhao;
Guo, Kai;
Yang, Lingyi;
Wang, Jun;
Li, Xiaoyi;
Wang, Zhuoying

Publication type:

Article

Apatinib combined with Keytruda treatment induces apoptosis of gastric carcinoma cells through CES4/miR‐616‐5p/DUSP2 axis.

Published in:

Basic & Clinical Pharmacology & Toxicology, 2021, v. 129, n. 5, p. 345, doi. 10.1111/bcpt.13641

By:

Zhang, Fengli;
Yin, Yanfen;
Xu, Wenwen;
Zhou, Zhou;
Sun, Xin;
Li, Ping

Publication type:

Article

Efficacy and safety of antiangiogenic therapy (bevacizumab or apatinib) plus chemotherapy in patients with platinum‑resistant recurrent ovarian cancer: A retrospective study.

Published in:

Oncology Letters, 2025, v. 29, n. 1, p. N.PAG, doi. 10.3892/ol.2024.14790

By:

Li, Huifen;
Xiao, Jianjun;
Tian, Muyou

Publication type:

Article

Effectiveness and safety of neoadjuvant apatinib in combination with capecitabine and oxaliplatin for the therapy of locally advanced colorectal cancer: A retrospective study.

Published in:

Oncology Letters, 2024, v. 27, n. 5, p. N.PAG, doi. 10.3892/ol.2024.14335

By:

Zhang, Tao;
Peng, Xinyu;
Li, Gang;
Yan, Liqi;
Zhang, Aimin;
Jia, Xiongjie

Publication type:

Article

Apatinib plus chemotherapy is associated with an improved tumor response, survival and tolerance compared with chemotherapy alone for advanced lung adenocarcinoma treatment.

Published in:

Oncology Letters, 2024, v. 27, n. 5, p. N.PAG, doi. 10.3892/ol.2024.14327

By:

Ye, Hua;
Yu, Wenwen;
Ni, Yangyang;
Bao, Xiaoqiong;
Zhang, Xie;
Li, Yunlei;
Chen, Ali;
Li, Jifa;
Zheng, Long

Publication type:

Article

Efficacy and safety of apatinib plus chemotherapy vs. chemotherapy alone for the treatment of advanced‑stage non‑small cell lung cancer: A meta‑analysis.

Published in:

Oncology Letters, 2024, v. 27, n. 1, p. N.PAG, doi. 10.3892/ol.2023.14158

By:

Qin, Shuai;
Han, Xiao;
Li, Zhuying

Publication type:

Article

Apatinib combined with trastuzumab and albumin-bound paclitaxel for treatment of HER2+ breast cancer with brain metastases resistant to anti-HER2 TKIs: A case report.

Published in:

Oncology Letters, 2023, v. 25, n. 2, p. N.PAG

By:

Huang, Jiayi;
Chen, Xiao;
Guo, Jinfeng;
Song, Lin;
Mu, Yanxi;
Zhao, Han;
Du, Caiwen

Publication type:

Article

Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism.

Published in:

Oncology Letters, 2020, v. 20, n. 3, p. 3035, doi. 10.3892/ol.2020.11857

By:

Yan, Zhen;
Gu, Yuan-Yuan;
Hu, Xiao-Di;
Zhao, Qun;
Kang, Hai-Li;
Wang, Miao;
Duan, Wei;
Guan, Yin

Publication type:

Article

IL-17 predicts the effect of TACE combined with apatinib in hepatocellular carcinoma.

Published in:

Clinical Hemorheology & Microcirculation, 2021, v. 77, n. 1, p. 37, doi. 10.3233/CH-200857

By:

Wu, Yongjuan;
Cheng, Guangyuan;
Chen, Hui;
Wang, Jingzhong;
Wang, Jiangtao;
Wang, Wanbi

Publication type:

Article

The Efficacy and Safety of Apatinib and Anlotinib in Advanced Non-Small Cell Lung Cancer.

Published in:

OncoTargets & Therapy, 2024, v. 17, p. 629, doi. 10.2147/OTT.S468932

By:

Wei, Xiao;
Zhao, Yun;
Yan, Wenyue;
Dai, Qigang;
Wu, Hui;
Miao, Yang;
Huang, Lei;
Liu, Qing;
Zhang, Xuyao;
Wang, Hongxia;
Liu, Yanan;
Zhang, Linlin

Publication type:

Article

Case Report and Review of Literature: Camrelizumab Combined with Fuzuloparib and Apatinib for Platinum-Resistant Recurrent Ovarian Cancer.

Published in:

2022

By:

Wu, Yawen;
Zhang, Xiaoyan;
Li, Lian;
Yang, Wen;
Yan, Zhifeng;
Gu, Chenglei;
Zhang, Zhe;
Zhou, Jiahuan;
Liu, Lulu;
Ye, Mingxia;
Meng, Yuanguang

Publication type:

Case Study

Traditional Chinese Medicine Astragalus Polysaccharide Enhanced Antitumor Effects of the Angiogenesis Inhibitor Apatinib in Pancreatic Cancer Cells on Proliferation, Invasiveness, and Apoptosis [Corrigendum].

Published in:

2022

By:

Wu, Jun;
Wang, Jing;
Su, Qiang;
Ding, Wei;
Li, Teng;
Yu, Junxian;
Cao, Bangwei

Publication type:

Correction Notice

Endostar Plus Apatinib Successfully Achieved Long Term Progression-Free Survival in Refractory Ovarian Cancer: A Case Report and Literature Review.

Published in:

OncoTargets & Therapy, 2021, v. 14, p. 5363, doi. 10.2147/OTT.S335139

By:

Xiao, Chunmei;
Xu, Fangye;
Wang, Rong;
Liang, Qi;
Shen, Kai;
Xu, Jiali;
Liu, Lianke

Publication type:

Article

Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial

Published in:

OncoTargets & Therapy, 2021, v. 14, p. 4859, doi. 10.2147/OTT.S316288

By:

Wang, Kang-Xin;
Cui, Ting-Yun;
Yang, Xu-Dong;
Wang, Guo-Qun;
Jiang, Qiu-Sheng;
Sun, Hui;
Jiang, Nan-Yuan;
Yong, Xiao-Min;
Shi, Chuan-Bing;
Ding, Yong-Bin;
Chen, Xiao-Feng;
Fang, Yue-Yu

Publication type:

Article

Efficacy and Safety of Apatinib for Elderly Patients with Advanced or Metastatic Gastric Cancer After Failure of at Least First-Line Chemotherapy: A Multi-Center, Single-Arm, Phase II Study.

Published in:

OncoTargets & Therapy, 2021, v. 14, p. 4499, doi. 10.2147/OTT.S322710

By:

Ren, Dengfeng;
Wang, Guoxiu;
Zhang, Yu;
Kan, Jie;
Dong, Qiuxia;
Zhao, Junhui;
Ji, Faxiang;
Li, Hao;
Luo, Yushuang;
Lin, Mingzhe;
Li, Guoyuan;
Liu, Zhibo;
Ma, Xinfu;
Guo, Qijing;
Zhao, Fuxing;
Shen, Guoshuang;
Zhao, Jiuda

Publication type:

Article

Apatinib Combined with Irinotecan in the Treatment of Advanced Small-Cell Esophageal Carcinoma: A Case Report.

Published in:

OncoTargets & Therapy, 2021, v. 14, p. 1989, doi. 10.2147/OTT.S295067

By:

Guo, Longhua;
Zou, Xiaofang;
Gu, Yinfang;
Yi, Lilan;
Zhao, Jingjing;
Wu, Guowu

Publication type:

Article

Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways.

Published in:

OncoTargets & Therapy, 2020, v. 13, p. 12325, doi. 10.2147/OTT.S276125

By:

Zhen, Hongchao;
Li, Guangxin;
Zhao, Pengfei;
Zhang, Ying;
Wang, Jing;
Yu, Junxian;
Cao, Bangwei

Publication type:

Article

Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.

Published in:

OncoTargets & Therapy, 2020, v. 13, p. 12683, doi. 10.2147/OTT.S286169

By:

Yuan, Guosheng;
Cheng, Xiao;
Li, Qi;
Zang, Mengya;
Huang, Wei;
Fan, Wenzhe;
Wu, Tao;
Ruan, Jian;
Dai, Wencong;
Yu, Wenxuan;
Chen, Mian;
Guo, Yabing;
Hu, Xiaoyun;
Chen, Jinzhang

Publication type:

Article

Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study.

Published in:

OncoTargets & Therapy, 2020, v. 13, p. 11529, doi. 10.2147/OTT.S277532

By:

Geng, Qian;
Shen, Hua;
Zhu, Wenyu;
Lu, Yingzhi;
Wang, Mengjie;
Jiang, Hua;
Li, Dongqing

Publication type:

Article

Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and β-Catenin Signaling.

Published in:

OncoTargets & Therapy, 2020, v. 13, p. 11031, doi. 10.2147/OTT.S266549

By:

Cai, Xiaomin;
Wei, Bin;
Li, Lele;
Chen, Xiaofeng;
Yang, Jing;
Li, Xiaofei;
Jiang, Xiaozheng;
Lv, Mu;
Li, Mingyang;
Lin, Yumeng;
Xu, Qiang;
Guo, Wenjie;
Gu, Yanhong

Publication type:

Article

Epigenetically regulated gene expression profiles decipher four molecular subtypes with prognostic and therapeutic implications in gastric cancer.

Published in:

Clinical Epigenetics, 2023, v. 15, n. 1, p. 1, doi. 10.1186/s13148-023-01478-w

By:

Weng, Siyuan;
Li, Minghao;
Deng, Jinhai;
Xu, Hui;
Ren, Yuqing;
Zhou, Zhaokai;
Wang, Libo;
Zhang, Yuyuan;
Xing, Zhe;
Li, Lifeng;
Liu, Zaoqu;
Han, Xinwei

Publication type:

Article

Effects of multi-kinase inhibitors on the activity of cytochrome P450 2J2.

Published in:

Xenobiotica, 2022, v. 52, n. 7, p. 669, doi. 10.1080/00498254.2022.2137068

By:

Kojima, Ayaka;
Nadai, Masayuki;
Murayama, Norie;
Yamazaki, Hiroshi;
Katoh, Miki

Publication type:

Article

Effects of Gemcitabine and Oxaliplatin Combined with Apatinib on Immune Function and Levels of SIL-2R and sicAM-1 in Patients with Gallbladder Cancer.

Published in:

Computational Intelligence & Neuroscience, 2022, p. 1, doi. 10.1155/2022/4959840

By:

Qu, Linlin;
Li, Kun;
Liu, Kui;
Hu, Weiyu

Publication type:

Article

"Highly Exposed Chinese Herbal Medicine" Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study.

Published in:

Dose-Response, 2021, v. 19, n. 4, p. 1, doi. 10.1177/15593258211055016

By:

Wang, Mingqi;
Jiang, Haili;
Zhang, Mei;
Chen, Yang;
Wang, Ting;
Li, Ping

Publication type:

Article

Clinical Effect Observation of Apatinib Combined with 131I for Radioiodine-Refractory Differentiated Thyroid Cancer and Prognostic Significance Analysis of Macrophage Inflammatory Protein-1α After Treatment: A Cell Regulation Study.

Published in:

International Journal of Morphology, 2024, v. 42, n. 2, p. 409, doi. 10.4067/s0717-95022024000200409

By:

Junru Liu;
Meng Li;
Weiying Zheng;
Mingzheng Wang

Publication type:

Article

A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas.

Published in:

BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-03132-x

By:

Zhou, Yan;
Li, Mei;
Zhang, Bing;
Yang, Cheng;
Wang, Yaling;
Zheng, Shuier;
Tang, Lina;
Zhou, Chenliang;
Qian, Guowei;
Huang, Yujing;
Yu, Wenxi;
Li, Hongtao;
Wang, Yonggang;
He, Aina;
Shen, Zan;
Zhang, Jianjun;
Li, Xiaoshuang;
Yang, Qingcheng;
Hu, Haiyan;
Yao, Yang

Publication type:

Article

A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.

Published in:

BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-03046-8

By:

Liu, Yaxin;
Wang, Wei;
Yin, Rutie;
Zhang, Youzhong;
Zhang, Yu;
Zhang, Keqiang;
Pan, Hongming;
Wang, Ke;
Lou, Ge;
Li, Guiling;
Zhang, Ruyan;
Li, Kun;
Rao, Jing;
Zhang, Ben;
Wang, Yuting;
Wang, Quanren;
Gao, Yunong;
Li, Huiping

Publication type:

Article

Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.

Published in:

BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-02841-7

By:

Li, Jin;
Qin, Shukui;
Wen, Lu;
Wang, Junsheng;
Deng, Wenying;
Guo, Weijian;
Jia, Tongfu;
Jiang, Da;
Zhang, Guifang;
He, Yifu;
Ba, Yi;
Zhong, Haijun;
Wang, Lin;
Lin, Xiaoyan;
Yang, Jianwei;
Zhao, Jun;
Bai, Yuxian;
Wu, Xiangyuan;
Gao, Feng;
Sun, Guogui

Publication type:

Article

Pretreatment lymphocyte-monocyte ratio (LMR) as a superior predictor of short-term progression outcomes in patients with gastric cancer receiving second- and later-line apatinib regimens.

Published in:

Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 12, p. 10715, doi. 10.1007/s00432-023-04976-9

By:

Shen, Hao;
Dang, Wenxi;
Su, Rixin;
Zhang, Zhihua;
Wu, Shusheng;
Li, Mengge;
Liu, Xudong;
He, Yifu

Publication type:

Article

Apatinib combined with olaparib induces ferroptosis via a p53-dependent manner in ovarian cancer.

Published in:

Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 11, p. 8681, doi. 10.1007/s00432-023-04811-1

By:

Yue, Wang;
Yupeng, Gu;
Jun, Cao;
Kui, Jiang

Publication type:

Article

Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study.

Published in:

Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 7, p. 4091, doi. 10.1007/s00432-022-04302-9

By:

Xu, Chao;
Xie, Xiaoli;
Kang, Ning;
Jiang, Huiqing

Publication type:

Article

Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.

Published in:

Cancer Immunology, Immunotherapy, 2022, v. 71, n. 11, p. 2597, doi. 10.1007/s00262-022-03174-9

By:

Jing, Chao;
Wang, Junyun;
Zhu, Mingyue;
Bai, Zhigang;
Zhao, Baoyi;
Zhang, Jun;
Yin, Jie;
Yang, Xiaobao;
Liu, Zongzhi;
Zhang, Zhongtao;
Deng, Wei

Publication type:

Article

The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus.

Published in:

Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-09609-8

By:

Zhang, Weihua;
Wu, Linxia;
Chen, Lei;
Sun, Tao;
Ren, Yanqiao;
Sun, Bo;
Zhu, Licheng;
Han, Ping;
Zheng, Chuansheng

Publication type:

Article

Safety and efficacy of apatinib in combination treatment versus apatinib as second-line treatment for advanced gastric cancer.

Published in:

Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2025.1587069

By:

Han, Zhang;
Yuanzeng, Zhu;
Gang, Wu;
Peichun, Sun

Publication type:

Article

Immune checkpoint inhibitors plus chemotherapy in the first-line treatment of young unresectable gastric cancer patients: a multicentre real-world study.

Published in:

Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2025.1476402

By:

Wang, Yingnan;
Li, Yan;
Liu, Zheng;
Liu, Jing;
Xu, Hongmei;
Zhang, Ruixing;
Zhang, Fengbin;
Guo, Zhanjun

Publication type:

Article

SOX combined with apatinib and camrelizumab in the treatment of resectable locally advanced gastric cancer: a case report.

Published in:

Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1410284

By:

JiKe Hu;
Xuemei Li;
Yunpeng Wang;
Bo Xu;
Puyi He;
Zhuanfang Wang;
Lijuan He;
Hao Chen

Publication type:

Article

Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study.

Published in:

Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2023.1298418

By:

Yunyan Mo;
Yufei Pan;
Bin Zhang;
Jian Zhang;
Yixin Su;
Zhengchun Liu;
Meiqing Luo;
Guanjie Qin;
Xiangyun Kong;
Rongjun Zhang;
Yu Pan;
Yi Liang;
Defeng Wang;
Yuejia Wei;
Hengwei Chen;
Wei Jiang

Publication type:

Article

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer.

Published in:

Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-30569-0

By:

Liu, Jieqiong;
Wang, Ying;
Tian, Zhenluan;
Lin, Ying;
Li, Hengyu;
Zhu, Zhaowen;
Liu, Qiang;
Su, Shicheng;
Zeng, Yinduo;
Jia, Weijuan;
Yang, Yaping;
Xu, Shengqiang;
Yao, Herui;
Jiang, Wen;
Song, Erwei

Publication type:

Article

Anti-proliferation effects of Apatinib in combination with Curcumin in breast cancer cells.

Published in:

Hormone Molecular Biology & Clinical Investigation, 2023, v. 44, n. 1, p. 27, doi. 10.1515/hmbci-2022-0036

By:

Farhoudi Sefidan Jadid, Mahdi;
Jahangirzadehd, Gholamreza;
Behroozi, Javad

Publication type:

Article

The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases.

Published in:

Annals of Medicine, 2023, v. 55, n. 1, p. 1, doi. 10.1080/07853890.2023.2218647

By:

Chen, Xuelian;
Bai, Xue;
Xie, Xiaofeng;
Huang, Jiayi;
Chen, Liping;
Song, Lin;
Lan, Xiaofeng;
Zhang, Qiuyi;
Guo, Jinfeng;
Du, Caiwen

Publication type:

Article

Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial.

Published in:

BMC Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12916-024-03564-z

By:

Tian, Wenjuan;
Ren, Yulan;
Lu, Jing;
Jing, Chuyu;
Zhang, Wei;
Li, Haiming;
Wang, Tingting;
Hou, Zhiguo;
Yang, Ting;
Zhu, Wenqing;
Zhang, Yi;
Shan, Boer;
Yang, Huijuan;
Cheng, Xi;
Wang, Huaying

Publication type:

Article

Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients.

Published in:

BMC Cancer, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12885-025-14207-8

By:

Wu, Shusheng;
Luo, Huiqin;
Chen, Wenju;
Liu, Xudong;
Li, Huimin;
Li, Mengge;
Ke, Lihong;
Niu, Jiayu;
Hu, Bing;
Xu, Huijun;
Wang, Gang;
Yan, Ying;
Cao, Lulu;
Hu, Xiaoxiu;
Li, Chenghui;
He, Yifu

Publication type:

Article